It has become clear that tumors result from excessive cell proliferation and a corresponding reduction in cell death caused by the successive accumulation of mutations in key regulatory target genes over time. During the 1980s, a number of oncogenes were characterized, whereas from the 1990s to the present, the emp- sis has shifted to tumor suppressor genes (TSGs). It has become clear that oncogenes and TSGs function in the same pathways, providing positive and negative growth regulatory activities. The signaling pathways controlled by these genes involve virtually every process in cell biology, including nuclear events, cell cycle, cell death, cytoskeletal, cell membrane, angiogenesis, and cell adhesion effects. Mu- tions in tumor suppressor genes have been identified in familial cancer syndromes, and the same genes in many cases have been found to be mutationally inactivated in sporadically occurring cancers. In their normal state, TSGs control cancer development and progression, as well as contribute to the sensitivity of cancers to a variety of therapeutics. Understanding the classes of TSGs, the biochemical pa- ways they function in, and how they are regulated provides an essential lesson in cancer biology. We cannot hope to advance our current knowledge and to develop new and more effective therapies without understanding the relevant pathways and how they influence the present approaches to therapy. Moreover, it is important to be able to access not only the powerful tools now available to discover these genes, but also their links to cell biology and growth control.

Malignant mesothelioma is an aggressive and fatal neoplasm of serous membranes that still shows a rising incidence worldwide. This book covers all the important aspects of the disease by bringing together contributions from selected experts in the fields of epidemiology, imaging, pathological diagnosis, therapy, genetics, and screening. Special emphasis is placed on the latest diagnostic techniques and current therapy standards. In addition, the mineralogy of asbestos is reviewed and clear advice is included on the analysis of tissue mineral fiber content. By providing a compact, scientifically based, and up-to-date overview of the management of malignant mesothelioma, this volume will be invaluable for all clinicians and pathologists who are engaged in the diagnosis and treatment of the disease or in related research.

Genetic susceptibility refers to how variations in a person 's genes increase or decrease his or her susceptibility to environmental factors, such as chemicals, radiation and lifestyle (diet and smoking). This volume will explore the latest findings in the area of genetic susceptibility to gastrointestinal cancers, focusing on molecular epidemiology, DNA repair, and gene-environment interactions to identify factors that affect the incidence of GI cancers. Topics will include germline susceptibility, including Mendelian patterns of inheritance and gene-environment interactions that lead to cancer etiology.

Hematopathology: Genomic Mechanisms of Neoplastic Diseases will keep physicians abreast of the rapid and complex changes in genomic medicine, as exemplified by the molecular pathology of hematologic malignancies. This timely volume will update physicians on the complexities of genomic lesions, as well as offer an integrated framework encompassing molecular diagnosis, the new WHO classification of hematologic neoplasms with focus on molecular pathology, prognostic value of molecular tests, and molecular monitoring of response to gene-targeted therapy. As such, it will be of great value to hematologists, oncologists, pathologists, internal medicine and pediatric specialists, as well as bioscientific staff and laboratorians in private hospitals and academic institutions.

This book presents a systematic survey of different local treatments in inflammatory joint diseases and their potential side effects and complications. Both surgical therapies and pharmaceutical strategies involving local or systemic application of anti-inflammatory and immunomodulating drugs are addressed. Special emphasis is placed on nuclear medicine therapy by intra-articular instillation of beta radiation emitters, known as radiosynoviorthesis or radiation synovectomy. Possible complications, in particular radionecrosis, infection, and thromboembolism, are described and available treatment strategies are examined in detail. In addition, radiation safety considerations are critically reviewed and relevant clinical questions are discussed. While radiosynoviorthesis is an effective and safe treatment if a proper indication is secured and if the application is performed by an experienced nuclear medicine physician, local complications can never be excluded with certainty. This book will support physicians who are engaged in the care and treatment of patients with inflammatory joint disease, approximately 30,000 of whom undergo radiosynoviorthesis in Europe each year.

Oncological imaging has thoroughly changed in the past decade, especially due to the introduction of PET and 18FDG. In "Positron Emission Tomography," expert referring specialists and professional imagers seek to help bridge some of the knowledge gaps in several oncological domains. The book s goal is to aid in the improvement of communicative competences: to communicate scan findings so that the referring specialist receives proper advice from the imager, and that, alternatively, the referring one provides the imager with appropriate clinical details to allow for a proper interpretation, and that the referring specialist is aware of the possibilities and limitations of the requested technology. While it focuses on FDG PET, other radiopharmaceuticals are covered as well, where appropriate. Written for the highly respected "Methods in Molecular Biology " series, this volume provides the kind of detailed description and implementation advice that is crucial for getting optimal results.

Authoritative and convenient, "Positron Emission Tomography" serves as an excellent reference for oncologists, surgeons, radiotherapists, radiologists, nuclear medicine physicians, and pathologists desiring a stronger synergy within their vital efforts."

The field of microRNA biology is really emerging in the last couple of years. Several investigators highlighted the importance of miRNAs in cancer. Although there is so much literature on microRNAs exist, a comprehensive book is still not available. Thus this book will be a great use to the scientists in the field of cancer biology. In addition, this book will be a good source of information for undergraduate, graduate students who want to develop their research careers in cancer biology.

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here

The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of pre-invasive disease and what the public health implications might be for wide-scale screening programmes. In the western world we already have experience of screening for cervical, breast, prostate and more recently colon cancer. As well as their potential benefits these programmes have financial and psychosocial implications which need to be carefully weighed. This is especially true since many pre-invasive lesions will not progress to cancer in a individual's lifetime. In addition, there are questions concerning whether screening reduces the cancer burden or in fact distorts the survival figures through lead-time bias. Secondly, at the level of epidemiology and molecular pathogenesis there are important questions regarding the aetiology of pre-invasive lesions; an understanding of which might lead to possible chemopreventive strategies. For example, it would be helpful to know the extent to which the likelihood of developing a pre-invasive lesion is influenced by lifestyle or genetic factors and how these factors influence the risk of progression to invasive disease. At the molecular level we need to understand the pathways and molecular mechanisms, both genetic and epigenetic, by which cells achieve the capacity to invade. Thirdly, in order make clinical progress we need biomarkers to identify and risk stratify individuals with pre-invasive lesions. These biomarkers might be applied to the serum as in Prostate Specific Antigen in prostate cancer or be applied to tissue samples, such as oestrogen receptor status in breast cancer. In order to utilize biomarkers in the context of a screening programme there are issue around the invasiveness of the test as well as its positive and negative predictive value. With advances in molecular imaging there is now the exciting possibility of incorporating a molecular tag to a non-invasive imaging modality. Fourthly, in order to justify screening early detection must be coupled to a treatment strategy. If the chemopreventive agent is very well tolerated, then as well as targeting high risk groups, one might consider treatment at the population level. Aspirin is one such drug which has been extensively assessed in the context of colon cancer chemoprevention trials. Trials of aspirin chemoprevention are now being applied to other cancers such as oesophageal adenocarcinoma and since many individuals take aspirin for .chemoprevention of cardiovascular disease the cancer incidence can be ascertained in these populations. In order to understand the more general issues raised from the discussions above it is useful to consider disease specific examples. Our understanding of pre-invasive disease varies according to the organ site and there are lessons to be learned from these experiences. For example, there is now the prospect of a vaccine for cervical cancer with important questions about how this might be applied to the high incidence areas of the developing world. On the other hand, ductal carcinoma in situ is currently treated by mastectomy which is more radical than the treatment received by many women with invasive disease. Oesophageal adenocarcinoma, which is my own area of expertise is interesting because of the rapid rise in incidence in the western world and the clinically accessible pre-invasive lesion called Barrett's oesophagus. However, most cases of Barrett's oesophagus remain undiagnosed and it is not yet clear how to effectively diagnose, monitor and treat this condition without recourse to mass endoscopy with substantial cost implications. In conclusion, in an era in which preventive medicine is a major concern for consumers, health-policy makers and politicians pre-invasive disease is likely to become a major part of cancer medicine.

One of the most important developments in the field of cardiovascular medicine over the last two decades has been recognition of the key role played by arterial thrombosis in the pathogenesis of acute coronary syndromes, ischemic complications of percutane- ous coronary revascularization, and coronary and peripheral atherosclerosis. The phar- macologic armamentarium directed against vascular thrombosis has thus expanded substantially during that time, with development of new fibrinolytic agents, low-molecu- lar-weight heparins, direct thrombin inhibitors, antagonists to platelet activation, and the platelet glycoprotein lIb/IlIa inhibitors. Though clinical investigations of these com- pounds have been marked by failures as well as successes, there is little doubt that enhanced antithrombotic therapies have markedly improved the outcome of patients undergoing coronary revascularization or with acute coronary syndromes. Glycoprotein IIblIlIa receptor antagonists were introduced into clinical practice to overcome the limitations of approaches that inhibit only individual pathways of platelet activation. Multiple mechanisms of platelet activation in response to different agonists converge on the platelet membrane glycoprotein IIblIlIa complex, the "final common pathway" of platelet aggregation. The clinical hemorrhagic syndrome caused by a rare inherited defect in this receptor (Glanzmann' s thrombasthenia), characterized by muco- cutaneous and postsurgical bleeding, but infrequent spontaneous organ (particularly central nervous system) bleeding, suggested that therapeutic inhibition of this receptor might be a potent, yet well-tolerated means of treating thrombotic disorders.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

During the last 20 years it has become increasingly clear that the tumor micro-environment, the tumor stroma with its cellular end extracellular components, plays an crucial role in regulating tumor growth and progression. This book on "Tumor-associated fibroblasts and their matrix" as part of the series on "Tumor-Microenvironment" is the first comprehensive discussion of these two main players of the tumor microenvironment. The best experts in this new area of tumor research and therapy review the role of these major components in the tumor stroma in the process of tumor development and progression. They discuss their interaction with other players such as blood vessels and immune cells, and show novel perspectives for tumor therapy. This compilation of excellent contributions of the best known experts in this important field in cancer research and therapy is a must for all scientists engaged in basic and clinical research. Increasing evidence of successful targeting of both cellular and matrix components in tumor therapy renders this book of particular interest for scientists engaged in pharmaceutical industry searching for new components for cancer therapy.

This book is a simple guide to the diagnosis, investigation, and treatment of all gynaecological cancers. It discusses the management of patients with gynaecological malignancies; considers the principles of chemotherapy, radiotherapy, and surgery; explains when and why each modality is used in treatment; covers the pathology of gynaecological cancer; discusses treatment of the advanced disease; and includes a chapter on the role of palliative care. The multidisciplinary approach reflects the cooperative practice in combined clinics.

Over the years of cancer investigation a lot of discoveries in this field were made, and many associations between various biological carcinogens and cancer were revealed. Some of them are credibly determined, thus these infectious agents (human papilloma virus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, human herpes virus 8, human T-cell lymphotropic virus 1, human immunodeficiency virus, Merkel cell polyomavirus, Helicobacter pylori, Opisthorchis viverrini, Clonorchis sinensis, Schistosoma haematobium) are recognized as carcinogens and probable carcinogens by International Agency for Research on Cancer (IARC). The problem is of large importance, since share of infectious agents-related cancer cases is steadily increasing, reaching 25% according to certain estimates. It is worth noting that many of cancer cases are caused by infectious agents other than -conventional ones- like HPV, EBV, HBV, HCV, H.pylori etc. In recent years, a number of significant breakthroughs in the field were performed, such as the discovery of the microbiota role in cancer causation."

This book represents an essential reference manual for all of the well-characterized leukemia-lymphoma cell lines currently available. It provides the most important facts, using the succinct and user-friendly format that has made the FactsBooks so popular with scientists and clinical researchers. Introductory chapters provide background and perspective for culturing malignant hematopoietic (blood forming) cell lines. These chapters are followed by over 400 comprehensive individual entries. Each cell line entry highlights essential clinical, immunological, genetic, and functional features and includes a comprehensive listing of references.
Key Features
* the full spectrum of malignant cell lines from all hematopoietic cell lineages
* sister cell lines and relevant subclones
* clinical data: patient, diagnosis, treatment status, and specimen source
* authentication of derivation and availability
* immunophenotype
* cytogenetic karyotype
* translocations and fusion genes
* receptor gene rearrangements and genetic alterations
* cell cultures aspects: establishment, medium, doubling time, growth
* cytochemical profile
* cytokine production and response to cytokines
* proto-oncogene and transcription factor expression/alteration
* functional features: differentiation induction, heterotransplantability
* special unique features
* key references

Antifolates are an important class of anticancer drugs originally developed as anti leu- kemic agents, but now used, usually in combination with other drugs, for the treatment of a wide range of tumors, notably carcinomas of the head and neck, breast, germ cell tumors, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and osteogenic sar- comas. 5-Fluorouracil and its prodrugs also target, in part, the folate-dependent enzyme, thymidylate synthase. Furthermore, folate supplementation in the form of leucovorin, modulates 5-fluororuacil activity. 5-Fluorouracil is widely used in the treatment of colorectal and gastric cancer and in combination for other solid tumors such as breast and head and neck cancers. Ongoing clinical trials with the newer antifolates suggest that the range of solid tumors where these agents will be of use may broaden further. Half a century ago, interesting scientific and clinical discoveries suggested that folie acid was a vitamin involved in vital cellular metabolic processes. The folate analogs, aminopterin and methotrexate, were synthesized by the American Cyanamid Company in an attempt to interfere with these processes and were shown to have anticancer activity by Farber and his colleagues. Hence, the principle of antimetabolite therapy for the treatment of cancer was established. Biomedical research over the following years led to a deeper understanding of the complex biochemical pharmacology of folates and antifolates. Selective antimicrobial agents were discovered, but more tumor-selective anticancer agents did not immediately emerge.

This volume is a valuable and timely resource for a broad audience with interests in basic and translational cancer biology, cancer drug development, as well as in the practice of personalized oncology. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Cancer Gene Networks aims to ensure successful results in the further study of this evolving and vital field. Ultimately these efforts will guide development of transformative strategies for cancer diagnosis and treatment.

This volume provides a general overview of the therapeutic potential of the essential oils in cancer and highlights some promising future directions. It integrates chemistry, pharmacology, and medicine while discussing bioactive essential oils in experimental models and clinical studies of cancer. The book is a valuable resource for all engaged in the study of natural products and their synthetic derivatives, particularly for those interested in academic research and pharmaceutical and food industries dedicated in the discovery of useful agents for the therapy or prevention of cancer.

¿Drs. Franco and Rohan bring together a timely and comprehensive set of reviews describing the biologic basis of carcinogenesis, issues related to measurement and interpretation of cancer precursors, site specific precancerous conditions, and control of cancer precursors ¿The book has several important strengths, most notably the wealth of current information on cancer precursors and related topics provided by an impressive cast of cancer researchers. ¿ it effectively provides specific and compelling reasons for studying cancer precursors, the most up-to-date and comprehensive collection of reviews on the topic, and a realistic picture of the complexities facing research of cancer precursors.¿ ¿American Journal of Epidemiology "In this book, Drs. Franco and Rohan have succeeded in preparing a comprehensive, timely, and critical review of the substantial progress that has been made in our understanding of cancer precursors. They have enlisted experts in the field who have contributed authoritative chapters to a wide variety of cancers with emphasis on the etiology and natural history, including the role of environmental and heritable factor that provoke normal cells to undergo malignant transformation. Epidemiologic data are linked whenever possible to molecular as well as clasical cellular pathology, providing a fuller understanding of the casual events and mechanisms that initiate the carcinogenic process." -From the Foreward by Joseph F. Fraumeni, Jr., M.D., M.S. Director, Division of Cancer Epidemiology and Genetics National Cancer Institute National Institutes of Health Rockville, MD This book provides an overview of the progress made in the last few years on the epidemiology, detection methods, and preventive stategies for cancer precursors. Contributors to the 25 chapters are among the world's most knowledgeable scientists in the areas of molecular pathology, epidemiology, and control of cancer precursors. Their reviews of the topic are accessible to a large professional base that includes basic cancer researchers, clinical oncologists, pathologists, molecular biologists, epidemiologists, nurses, health professionals working on policy implications, and graduate students in cancer-related fields. Divided into five sections, the book begins with brief overviews of the molecular basis of carcinogenesis and of the histological aspects of cancer precursors. Issues related to the measurement, interpretation, and the study of precursor lesions are addressed in Part II, including timely chapters on epidemiologic approaches to studying intermediate endpoints, the impact of measurement error, and methods of processing biological specimens for molecular epidemiology studies. The main section of the text is found in Part III, with chapters on cancer precursors at the most important anatomical sites at which solid tumors occur, including the lung, breast, colon, esophagus, and prostate. The site-specific reviews include discussions of the epidemiology of those lesions, and, where appropriate, aspects of their detection and prevention. The final sections of the book feature valuable overviews on screening and prevention strategies and the role of evidence-based medicine in judging the value of such strategies for national and international policy guidelines on cancer control.

This comprehensive text provides a much-needed review of a disease that is currently garnering the interest of molecular biologists, translational scientists, and clinicians. The volume includes emerging developments in the molecular genetics of endometrial carcinoma. In addition to covering the basic genetics of endometrial carcinoma, chapters also cover a wide range of signaling pathways implicated in endometrial carcinoma. A section of the book includes a number of genetically engineered mouse models, which contribute to understanding the role of various genetic alterations in the development and progression of endometrial carcinoma. These models also provide preclinical models for developing effective targeted therapeutic approaches. Endometrial carcinoma is the most common malignancy of the female genital tract in the United States and the number of cases continues to increase around the world. This book is a meant to serve as a resource for a wide range of scientists, from molecular geneticists to signal transduction biologists, as well as to both clinicians and scientists interested in developing targeted therapeutic approaches for women with endometrial carcinoma.

Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.

This textbook is unique in that it is the first European text for nurses practicing beyond the novice level in cancer nursing. Previously European cancer nurses have had to rely on North American texts, which are not always culturally transferable. The book presents a synthesis of important issues, which underpin the practice of advanced cancer nursing and are vital to experiencedpractitioners in moving cancer nursing forward. The central concerns of the book reflect the emerging roles of the advanced specialist practitioner and include advanced practice, education, management and research. The text is written by recognised cancernursing experts from throughout Europe who collectively are involved in shaping the future of cancer nursing across the continent.Unique collection of authors from Europe who are recognised for their respective roles in shaping the future of cancer nursing Key text for those engaging in postgraduate studies on practicing at an advanced level.Explores the different domains of advanced practice in cancer nursing which are necessary to move the specialty forward Unique European text for cancer nurses wishing to develop expert knowledgeBased on current research data Produced under the auspices of EONS

This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific indications and results for different tumor entities. Clinical trial concepts and detailed treatment protocols are also presented. This book is essential reading for researchers and clinicians engaged in seeking advanced therapeutic options for cancer patients worldwide.

With the coming of the new millennium we are witnessing a revolution in our understanding of cancer genetics. These are very exciting times. Today we have at our disposal the technology to diagnose abnormalities in our cancer genes and the means to correct the deficit and very soon we will have the complete sequence of the human genome. With the use of gene chip technology the way doctors will be able to assess patients will change completely. Today we can diagnose abnormalities in ten thousand genes and within a short period of time we will be able to screen through our genome and discover potential abnormalities in our proto-oncogenes, tumour suppressor genes, differentiating genes, apoptotic genes and pro-inflammatory genes. In this book various authors have highlighted specific genes that could be expressed, overexpressed, neutralised or h- nessed to achieve cancer control. The problem of transferring the therapeutic gene into the cancer cell has been partly addressed with major developments in the field of naked plasmid DNA, adenovirus, retrovirus and adeno-associated viruses. However, further improvements are yet to be made to achieve significant gene transfer. Gene expression, in particular specificity of gene transfer, is obviously an important issue and one which is highlighted in this book by the use of specific promoter.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here once again, outstanding and original reviews are presented.
Key Features
* New Paradigms for the Treatment of Cancer: The Role of Anti-aiogenesis Agents
* The Hepatocyte Growth Factor/Met Pathway in Development, Tumorigenesis, and B-Cell Differentiation
* Clinical Targets for Anti-metastasis Therapy
* Animal Models of Melanoma: Recent Advances and Future Prospects
* The Indispensable Role of Microenvironment in the Natural History of Low-Grade B-Cell Neoplasms
* Epstein-Barr Virus Latency: LMP2, a Regulator or Means for Epstein-Barr Birus
* Biochemistry and Pathological Importance of Mucin-Associated Antigens in Gastrointenstinal Neoplasia
* Studies on Polyomavirus Persistence and Polyomavirus-Induced Tumor Development in Relation to the Immune System